These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 25599649)

  • 1. Pharmacokinetics, safety and efficacy of ritonavir-boosted atazanavir (300/100 mg once daily) in HIV-1-infected pregnant women.
    Lê MP; Mandelbrot L; Descamps D; Soulié C; Ichou H; Bourgeois-Moine A; Damond F; Lariven S; Valantin MA; Landman R; Faucher P; Tubiana R; Duro D; Meier F; Legac S; Bourse P; Mortier E; Dommergues M; Calvez V; Matheron S; Peytavin G
    Antivir Ther; 2015; 20(5):507-13. PubMed ID: 25599649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women.
    Conradie F; Zorrilla C; Josipovic D; Botes M; Osiyemi O; Vandeloise E; Eley T; Child M; Bertz R; Hu W; Wirtz V; McGrath D
    HIV Med; 2011 Oct; 12(9):570-9. PubMed ID: 21569187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atazanavir exposure is effective during pregnancy regardless of tenofovir use.
    Colbers A; Hawkins D; Hidalgo-Tenorio C; van der Ende M; Gingelmaier A; Weizsäcker K; Kabeya K; Taylor G; Rockstroh J; Lambert J; Moltó J; Wyen C; Sadiq ST; Ivanovic J; Giaquinto C; Burger D;
    Antivir Ther; 2015; 20(1):57-64. PubMed ID: 24992294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and Pharmacodynamics of Atazanavir in HIV-1-Infected Children Treated With Atazanavir Powder and Ritonavir: Combined Analysis of the PRINCE-1 and -2 Studies.
    Sevinsky H; Zaru L; Wang R; Xu X; Pikora C; Correll TA; Eley T
    Pediatr Infect Dis J; 2018 Jun; 37(6):e157-e165. PubMed ID: 29206748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic drug monitoring of atazanavir/ritonavir in pregnancy.
    Else LJ; Jackson V; Brennan M; Back DJ; Khoo SH; Coulter-Smith S; Lambert JS
    HIV Med; 2014 Nov; 15(10):604-10. PubMed ID: 24825070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atazanavir intracellular concentrations remain stable during pregnancy in HIV-infected patients.
    Focà E; Calcagno A; Bonito A; Simiele M; Domenighini E; D'Avolio A; Quiros Roldan E; Trentini L; Casari S; Di Perri G; Castelli F; Bonora S
    J Antimicrob Chemother; 2017 Nov; 72(11):3163-3166. PubMed ID: 28961777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic and kidney disorders correlate with high atazanavir concentrations in HIV-infected patients: is it time to revise atazanavir dosages?
    Gervasoni C; Meraviglia P; Minisci D; Ferraris L; Riva A; Landonio S; Cozzi V; Charbe N; Molinari L; Rizzardini G; Clementi E; Galli M; Cattaneo D
    PLoS One; 2015; 10(4):e0123670. PubMed ID: 25875091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection.
    Fabbiani M; Di Giambenedetto S; Ragazzoni E; Colafigli M; Prosperi M; Cauda R; Navarra P; De Luca A
    HIV Med; 2010 May; 11(5):326-33. PubMed ID: 20070407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential association between rosuvastatin use and high atazanavir trough concentrations in ritonavir-treated HIV-infected patients.
    Gervasoni C; Riva A; Rizzardini G; Clementi E; Galli M; Cattaneo D
    Antivir Ther; 2015; 20(4):449-51. PubMed ID: 25279606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lopinavir and atazanavir in pregnancy: comparable infant outcomes, virological efficacies and preterm delivery rates.
    Perry ME; Taylor GP; Sabin CA; Conway K; Flanagan S; Dwyer E; Stevenson J; Mulka L; McKendry A; Williams E; Barbour A; Dermont S; Roedling S; Shah R; Anderson J; Rodgers M; Wood C; Sarner L; Hay P; Hawkins D; deRuiter A
    HIV Med; 2016 Jan; 17(1):28-35. PubMed ID: 26200570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of total and unbound darunavir in HIV-1-infected pregnant women.
    Colbers A; Moltó J; Ivanovic J; Kabeya K; Hawkins D; Gingelmaier A; Taylor G; Weizsäcker K; Sadiq ST; Van der Ende M; Giaquinto C; Burger D;
    J Antimicrob Chemother; 2015 Feb; 70(2):534-42. PubMed ID: 25326090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients.
    Squires KE; Young B; Dejesus E; Bellos N; Murphy D; Zhao HH; Patel LG; Ross LL; Wannamaker PG; Shaefer MS;
    AIDS; 2010 Aug; 24(13):2019-27. PubMed ID: 20613461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of "unboosting" atazanavir in a randomized controlled trial among HIV-infected patients receiving tenofovir DF.
    Harris M; Ganase B; Watson B; Hull MW; Guillemi SA; Zhang W; Saeedi R; Harrigan PR
    HIV Clin Trials; 2017 Jan; 18(1):39-47. PubMed ID: 28067119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacodynamics of atazanavir-containing antiretroviral regimens, with or without ritonavir, in patients who are HIV-positive and treatment-naïve.
    Bertz RJ; Persson A; Chung E; Zhu L; Zhang J; McGrath D; Grasela D
    Pharmacotherapy; 2013 Mar; 33(3):284-94. PubMed ID: 23456732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: a cohort study.
    Gantner P; Koeppel C; Partisani M; Batard ML; Bernard-Henry C; Cheneau C; De Mautort E; Priester M; Muret P; Sueur C; Fafi-Kremer S; Rey D
    Scand J Infect Dis; 2014 Dec; 46(12):838-45. PubMed ID: 25229167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Efficacy, Tolerability, and Renal Safety of Atazanavir/Ritonavir-based Antiretroviral Therapy in a Cohort of Treatment-Naïve Patients with HIV-1 Infection: the REMAIN Study.
    Teófilo E; Rocha-Pereira N; Kuhlmann B; Antela A; Knechten H; Santos J; Jiménez-Expósito MJ;
    HIV Clin Trials; 2016 Feb; 17(1):17-28. PubMed ID: 26899539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atazanavir in pregnancy: impact on neonatal hyperbilirubinemia.
    Mandelbrot L; Mazy F; Floch-Tudal C; Meier F; Azria E; Crenn-Hebert C; Treluyer JM; Herinomenzanahary E; Ferreira C; Peytavin G
    Eur J Obstet Gynecol Reprod Biol; 2011 Jul; 157(1):18-21. PubMed ID: 21492993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atazanavir pharmacokinetics, efficacy and safety in pregnancy: a systematic review.
    Eley T; Bertz R; Hardy H; Burger D
    Antivir Ther; 2013; 18(3):361-75. PubMed ID: 23676668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.
    Molina JM; Andrade-Villanueva J; Echevarria J; Chetchotisakd P; Corral J; David N; Moyle G; Mancini M; Percival L; Yang R; Thiry A; McGrath D;
    Lancet; 2008 Aug; 372(9639):646-55. PubMed ID: 18722869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of saquinavir/ritonavir in HIV-infected pregnant women: INEMA cohort.
    Brunet C; Reliquet V; Jovelin T; Venisse N; Winer N; Bui E; Le Moal G; Perfezou P; De Saint Martin L; Raffi F
    Med Mal Infect; 2012 Sep; 42(9):421-8. PubMed ID: 22938775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.